A higher V617F allele burden may be a risk factor for hemorrhagic events in younger patients with polycythemia vera.

Objectives: Hemorrhagic events are a rare but potentially fatal complication in patients with polycythemia vera (PV).

Methods: We analyzed the characteristics of hemorrhagic events in 267 patients with PV.

Results: A median follow-up of 4.

A New Histology-Based Prognostic Index for Aggressive T-Cell lymphoma: Preliminary Results of the "TCL Urayasu Classification".

Aggressive mature T-cell lymphoma (TCL) is a disease that carries a poor prognosis. We analyzed the expression of 22 tumor cell functional proteins in 16 randomly selected patients with TCL. Immunohistochemistry was performed in paraffin-embedded tumor tissue sections to determine the protein expression statuses in tumor cells.

Case report: Ensitrelvir for treatment of persistent COVID-19 in lymphoma patients: a report of two cases.

Persistent COVID-19 is a well recognized issue of concern in patients with hematological malignancies. Such patients are not only at risk of mortality due to the infection itself, but are also at risk of suboptimal malignancy-related outcomes because of delays and terminations of chemotherapy. We report two lymphoma patients with heavily pretreated persistent COVID-19 in which ensitrelvir brought about radical changes in the clinical course leading to rapid remissions.

Impact of non-driver gene mutations on thrombo-haemorrhagic events in ET patients.

Risk-adapted therapy is recommended to prevent major clinical complications, such as thrombo-haemorrhagic events, in patients with essential thrombocythaemia (ET). In this study, we analysed the association between non-driver gene mutations and thrombo-haemorrhagic events in 579 patients with ET. ASXL1 and TP53 mutations were frequently identified in patients with ET complicated by thrombosis (22.

gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan.

Objectives: Since mutation is a rare driver gene mutation found in a small number of essential thrombocythemia (ET) patients, the clinical characteristics of patients with mutations and their association with thrombotic events have not yet been elucidated in Japan.

Methods: We enrolled 579 Japanese ET patients based on the diagnostic criteria of the WHO classification 2017 and compared clinical characteristics of -mutated patients ( = 22; 3.8%) to V617F-mutated ( = 299; 51.